Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages

Brain

Volumn 139, Issue 5, 2016, Pages 1539-1550

  Schwarz, Adam J ^a   Yu, Peng ^a   Miller, Bradley B ^a   Shcherbinin, Sergey ^a   Dickson, James ^b   Navitsky, Michael ^b   Joshi, Abhinay D ^b   Devous, Michael D ^b   Mintun, Mark S ^b  

^a ELI LILLY AND COMPANY   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

18F AV 1451; Braak staging; imaging; positron emission tomography (PET); tau

Indexed keywords

AMYLOID; FLORTAUCIPIR F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE;

ADULT; AGED; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; BRAAK STAGING; BRAIN REGION; COGNITION; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAGING; STANDARDIZED UPTAKE VALUE; TEMPORAL LOBE; VERY ELDERLY; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; METABOLISM; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; CARBOLINES; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; NEUROIMAGING; OCCIPITAL LOBE; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TEMPORAL LOBE; YOUNG ADULT;

EID: 84962811108     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww023     Document Type: Article

References (28)

1. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008; 18: 484-96.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
3. Amunts K, Kedo O, Kindler M, Pieperhoff P, Mohlberg H, Shah NJ, et al. Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol (Berl) 2005; 210: 343-52.
4. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
5. Braak H, Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
6. Braak H, Thal DR, Ghebremedhin E, Del Tredici K Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70: 960-9.
7. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
8. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457-68.
9. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloidb plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-78.
10. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755-66.
11. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
12. Jack CR Jr. PART and SNAP. Acta Neuropathol 2014; 128: 773-6.
13. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
14. Joshi A, Pontecorvo M, Lu M, Skovronsky DM, Mintun M, Devous MD A semi-automated method for quantification of florbetapir F 18 PET images. J Nucl Med 2015; 56: 1736-41.
15. Marquie M, Normandin MD, Vanderburg CR, Costantino I, Bien EA, Rycyna LG, et al. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787-800.
16. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094-108.
17. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
18. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
19. Murray ME, Graff-Radford N, Ross OA, Petersen RC, Duara R, Dickson D Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10: 785-96.
20. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015; 138 (Pt 5): 1370-81.
21. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep 2014; 14: 500.
22. Stancu IC, Vasconcelos B, Terwel D, Dewachter I Models of betaamyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener 2014; 9: 51.
23. Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 2015; 11: 975-85.
24. Thal DR, Rub U, Orantes M, Braak H Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800.
25. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013; 1: 65.
26. Toledo JB, Xie SX, Trojanowski JQ, Shaw LM Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol 2013; 126: 659-70.
27. Villemagne VL, Okamura N In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014; 10 (Suppl 3): S254-64.
28. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013; 9: 666-76.